Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the safety and tolerability of re-dosing with intravenous (iv) otelixizumab in newly diagnosed adult subjects with type 1 diabetes mellitus.

Next Previous
Search
Trial Profile

Evaluation of the safety and tolerability of re-dosing with intravenous (iv) otelixizumab in newly diagnosed adult subjects with type 1 diabetes mellitus.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Otelixizumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 20 Apr 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
  • 17 Jun 2011 Actual initiation date (Nov 2010) added as reported by ClinicalTrials.gov.
  • 17 Jun 2011 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top